(Q57085810)

2

0 references

M. Bergui

3

0 references

E. Versino

4

0 references

M. A. Bassano

5

0 references

E. Verdun

6

0 references

B. Ferrero

7

0 references

C. Rivoiro

8

0 references

C. Ferrero

9

0 references

E. Picco

10

0 references

P. Ripellino

11

0 references

D. Viglietti

12

0 references

G. Giuliani

13

0 references

E. Montanari

14

0 references

M. Clerico

https://scigraph.springernature.com/pub.10.1007/s00415-008-0879-6

15

0 references

publication date

September 2008

0 references

published in

Journal of Neurology

0 references

volume

255

0 references

issue

9

0 references

page(s)

1315-1323

0 references

exact match

0 references

cites work

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0879-6

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0879-6

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0879-6

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0879-6

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0879-6

Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?

21 January 2018

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Regression to the mean: treatment effect without the intervention.

1 reference

12 December 2020

Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

12 December 2020

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

12 December 2020

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy

1 reference

12 December 2020

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

1 reference

12 December 2020

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

1 reference

12 December 2020

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

A novel sensitive and selective bioassay for human type I interferons

1 reference

12 December 2020